Erasca, Inc. reports results for the quarter ended June 30 - Earnings Summary
Erasca, Inc. reports results for the quarter ended June 30 - Earnings Summary
Erasca, Inc. ERAS.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -12 cents. The mean expectation of eleven analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -1 cents per share.
Reported revenue was zero; analysts expected zero.
Erasca, Inc.'s reported EPS for the quarter was a loss of 14 cents.
The company reported a quarterly loss of $44.08 million.
Erasca, Inc. shares had fallen by 1.1% this quarter and gained 387.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.9% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Erasca, Inc. is $21.50, about 15.7% above its last closing price of $18.12
This summary was machine generated from LSEG data August 11 at 08:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.10 | -0.14 | Missed |
Mar. 31 2026 | -0.21 | -0.60 | Missed |
Dec. 31 2025 | -0.11 | -0.10 | Beat |
Sep. 30 2025 | -0.10 | -0.11 | Missed |